Pangaea Data provides a novel AI-driven product to characterize patients by unlocking and summarizing insights from their data in a scalable and federated privacy-preserving manner. This is helping clinicians at healthcare and pharmaceutical companies to discover new clinically actionable insights, and map patient journeys and disease trajectories. For example, oncologists applied this capability to discover 6x more cancer patients with cachexia, which helped them reduce the cost of treatment by 50% and potentially save £1 billion annually. Clinicians at pharmaceutical companies have benefitted from these capabilities by finding more suitable patients and improving screening success rates for new therapies and clinical trials.
NVIDIA Inception will allow Pangaea to further accelerate its development and scale its work, assisting its team by providing access to cutting-edge technology, support, and training. The program will also offer Pangaea the opportunity to collaborate with industry-leading experts and other AI-driven organizations.
“We launched Pangaea to help patients and clinicians across the global pharmaceutical and healthcare industry by discovering new clinically valid knowledge from health data in a privacy-preserving manner. Joining NVIDIA Inception will help Pangaea to further accelerate this work and our development,” said Dr. Vibhor Gupta, Pangaea’s CEO. “We look forward to collaborating with NVIDIA and its scientific and technical experts to address some of the toughest challenges in life sciences and healthcare today.”
NVIDIA Inception helps startups during critical stages of product development, prototyping, and deployment. Every NVIDIA Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, marketing support, and technology assistance, which provides startups with the fundamental tools to help them grow.
Pangaea Data is a South San Francisco and London-based provider of novel AI-driven product to characterize patients by mapping their journey and disease trajectories based on extraction and summarization of intelligence from patients records in a scalable and privacy-preserving manner. The founders (Dr. Vibhor Gupta and Prof. Yike Guo) have attracted more than $200 million through their research. The company is advised by leading authorities from life sciences and healthcare and has published its work in high-impact, peer-reviewed journals, and conferences, which is also available at www.pangaeadata.ai/insights/.